Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olorinab - Pfizer

Drug Profile

Olorinab - Pfizer

Alternative Names: APD-371

Latest Information Update: 16 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Pfizer
  • Class Analgesics; Pyrazoles; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome; Pain

Most Recent Events

  • 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
  • 04 Feb 2022 Arena pharmaceuticals has patent protection for olorinab in USA, China, Japan, Canada, India, Russia, South Korea and Australia, Europe, Venezuela, and Brazil (Arena pharmaceuticals form 10-k, February 2022)
  • 03 Oct 2021 Efficacy and safety data from phase IIb CAPTIVATE trial in Pain presented at 29th United European Gastroenterology Week (UEGW-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top